1
|
Margineanu I, Butnaru T, Lam M, Baiceanu D, Dragomir R, Arbore AS, Mahler B, Munteanu I, Mihaltan F, Akkerman O, Alffenaar JW, Stienstra Y. Tuberculosis impacts multiple aspects in quality of life in a Romanian cohort of drug-susceptible and drug resistant patients: A patient-reported outcome measures study. Trop Med Int Health 2024. [PMID: 38794852 DOI: 10.1111/tmi.13996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2024]
Abstract
BACKGROUND Tuberculosis (TB), and especially its drug resistant forms, is responsible for not only significant mortality, but also considerable morbidity, still under-quantified. This study used four Patient-Reported Outcome Measures (PROMS) to assess the status of persons affected by drug-susceptible and drug-resistant TB during their TB treatment or after treatment completion, in Romania, the highest TB burden country in the EU. METHODS People affected by TB in two different regions in Romania were included during and after treatment, following a cross-sectional design. PROMs used were SF-36, EQ-5D-5L, WPAI and the app-based audiometry screening tool 'uHear.' Descriptive statistics and relevant statistical tests were used to compare groups between themselves and with the general Romanian population. RESULTS Both patients with drug-susceptible and drug-resistant TB experience, with drug-resistant patients experiencing statistically significantly more pain and hearing loss. PROMs show some improvement in the after-treatment group; however, compared with the general Romanian population for which data were available, all groups scored lower on all outcome measures. CONCLUSION PROMs offer the possibility of obtaining a more comprehensive view of patients' status, by involving them directly in the medical process and could guide a rehabilitation strategy.
Collapse
Affiliation(s)
- Ioana Margineanu
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centrum Groningen, Groningen, the Netherlands
| | - Teodora Butnaru
- Department of Respiratory Medicine, Marius Nasta Tb Institute, Bucharest, Romania
| | - Marjolein Lam
- Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - Dragos Baiceanu
- Department of Respiratory Medicine, Marius Nasta Tb Institute, Bucharest, Romania
| | - Raluca Dragomir
- Department of Respiratory Medicine, Marius Nasta Tb Institute, Bucharest, Romania
| | | | - Beatrice Mahler
- Department of Respiratory Medicine, Marius Nasta Tb Institute, Bucharest, Romania
| | - Ioana Munteanu
- Department of Respiratory Medicine, Marius Nasta Tb Institute, Bucharest, Romania
| | - Florin Mihaltan
- Department of Respiratory Medicine, Marius Nasta Tb Institute, Bucharest, Romania
| | - Onno Akkerman
- Department of Pulmonary diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
- Tuberculosis Center Beatrixoord, University of Groningen, University Medical Center Groningen, Haren, the Netherlands
| | - Jan-Willem Alffenaar
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centrum Groningen, Groningen, the Netherlands
- School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
- Westmead Hospital, Westmead, New South Wales, Australia
- Sydney Institute for Infectious Diseases, University of Sydney, Sydney, New South Wales, Australia
| | - Ymkje Stienstra
- Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
| |
Collapse
|
2
|
Bhavsar KN, Chaudhari AV, Chauhan JM, Patel RB, Contractor JA, Shamaliya KD, Desai PJ, Roy PP, Patel HC. Combined Retrospective-Prospective Cohort Study to Know the Risk of Sensorineural Hearing Loss in Patients of Drug Resistant TB Receiving Anti Tuberculous Treatment (ATT) at Tertiary Care Centre in South Gujarat. Indian J Otolaryngol Head Neck Surg 2023; 75:3185-3190. [PMID: 37974733 PMCID: PMC10645687 DOI: 10.1007/s12070-023-03702-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Accepted: 03/16/2023] [Indexed: 11/19/2023] Open
Abstract
Combined retrospective-prospective cohort study was done to know the risk of sensorineural hearing loss in patients of drug resistant Tuberculosis (TB) receiving Anti Tuberculous Treatment (ATT) at tertiary care centre in South Gujarat. Study was done by using retrospective and prospective data of the patients of drug resistant TB of NCHS who received injectable ATT and referred by department of Respiratory Medicine to ENT department for purpose of hearing evaluation pre and post treatment (Case cohort). Age and sex matched control cohort was also used which includes patients of non-drug resistant TB who were not receiving Injectable ATT. Incidence of SNHL in patients taking ATT for drug resistant tuberculosis in our study was 33.9%. The Relative Risk of SNHL was 14.3%. The Attributable Risk of SNHL (preventable SNHL) was 93%.
Collapse
Affiliation(s)
- Khushi N. Bhavsar
- Department of Otorhinolaryngology, Government Medical College, Surat, Gujarat India
| | | | - Jahanvika M. Chauhan
- Department of Otorhinolaryngology, Government Medical College, Surat, Gujarat India
| | - Rahulkumar B. Patel
- Department of Otorhinolaryngology, Government Medical College, Surat, Gujarat India
| | - Jaymin A. Contractor
- Department of Otorhinolaryngology, Government Medical College, Surat, Gujarat India
| | - Khyati D. Shamaliya
- Department of Pulmonary Medicine, Government Medical College, Surat, Gujarat India
| | - Pururava J. Desai
- Department of Otorhinolaryngology, Government Medical College, Surat, Gujarat India
| | - Prachi P. Roy
- Department of Otorhinolaryngology, Government Medical College, Surat, Gujarat India
| | - Hiteshri C. Patel
- Department of Community Medicine, Government Medical College, Surat, Gujarat India
| |
Collapse
|
3
|
Li Y, Li A, Wang C, Jin X, Zhang Y, Lu L, Wang SL, Gao X. The Ganglioside Monosialotetrahexosylganglioside Protects Auditory Hair Cells Against Neomycin-Induced Cytotoxicity Through Mitochondrial Antioxidation: An in vitro Study. Front Cell Neurosci 2021; 15:751867. [PMID: 34646124 PMCID: PMC8502895 DOI: 10.3389/fncel.2021.751867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Accepted: 09/06/2021] [Indexed: 11/13/2022] Open
Abstract
Neomycin is a common ototoxic aminoglycoside antibiotic that causes sensory hearing disorders worldwide, and monosialotetrahexosylganglioside (GM1) is reported to have antioxidant effects that protect various cells. However, little is known about the effect of GM1 on neomycin-induced hair cell (HC) ototoxic damage and related mechanism. In this study, cochlear HC-like HEI-OC-1 cells along with whole-organ explant cultures were used to establish an in vitro neomycin-induced HC damage model, and then the apoptosis rate, the balance of oxidative and antioxidant gene expression, reactive oxygen species (ROS) levels and mitochondrial membrane potential (MMP) were measured. GM1 could maintain the balance of oxidative and antioxidant gene expression, inhibit the accumulation of ROS and proapoptotic gene expression, promoted antioxidant gene expression, and reduce apoptosis after neomycin exposure in HEI-OC-1 cells and cultured cochlear HCs. These results suggested that GM1 could reduce ROS aggregation, maintain mitochondrial function, and improve HC viability in the presence of neomycin, possibly through mitochondrial antioxidation. Hence, GM1 may have potential clinical value in protecting against aminoglycoside-induced HC injury.
Collapse
Affiliation(s)
- Yujin Li
- Department of Otolaryngology-Head and Neck Surgery, Nanjing Drum Tower Clinical College of Nanjing Medical University, Nanjing, China.,Department of Otolaryngology-Head and Neck Surgery, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, China
| | - Ao Li
- Department of Otolaryngology-Head and Neck Surgery, Nanjing Drum Tower Clinical College of Nanjing Medical University, Nanjing, China.,Research Institute of Otolaryngology, Nanjing, China.,Jiangsu Provincial Key Medical Discipline (Laboratory), Department of Otolaryngology-Head and Neck Surgery, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - Chao Wang
- School of Public Health, Nanjing Medical University, Nanjing, China
| | - Xin Jin
- Department of Otolaryngology-Head and Neck Surgery, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, China
| | - Yaoting Zhang
- Department of Otolaryngology-Head and Neck Surgery, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, China
| | - Ling Lu
- Department of Otolaryngology-Head and Neck Surgery, Nanjing Drum Tower Clinical College of Nanjing Medical University, Nanjing, China.,Research Institute of Otolaryngology, Nanjing, China.,Jiangsu Provincial Key Medical Discipline (Laboratory), Department of Otolaryngology-Head and Neck Surgery, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - Shou-Lin Wang
- School of Public Health, Nanjing Medical University, Nanjing, China
| | - Xia Gao
- Department of Otolaryngology-Head and Neck Surgery, Nanjing Drum Tower Clinical College of Nanjing Medical University, Nanjing, China.,Research Institute of Otolaryngology, Nanjing, China.,Jiangsu Provincial Key Medical Discipline (Laboratory), Department of Otolaryngology-Head and Neck Surgery, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| |
Collapse
|
4
|
Rybak LP, Ramkumar V, Mukherjea D. Ototoxicity of Non-aminoglycoside Antibiotics. Front Neurol 2021; 12:652674. [PMID: 33767665 PMCID: PMC7985331 DOI: 10.3389/fneur.2021.652674] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Accepted: 02/16/2021] [Indexed: 12/17/2022] Open
Abstract
It is well-known that aminoglycoside antibiotics can cause significant hearing loss and vestibular deficits that have been described in animal studies and in clinical reports. The purpose of this review is to summarize relevant preclinical and clinical publications that discuss the ototoxicity of non-aminoglycoside antibiotics. The major classes of antibiotics other than aminoglycosides that have been associated with hearing loss in animal studies and in patients are discussed in this report. These antibiotics include: capreomycin, a polypeptide antibiotic that has been used to treat patients with drug-resistant tuberculosis, particularly in developing nations; the macrolides, including erythromycin, azithromycin and clarithromycin; and vancomycin. These antibiotics have been associated with ototoxicity, particularly in neonates. It is critical to be aware of the ototoxic potential of these antibiotics since so much attention has been given to the ototoxicity of aminoglycoside antibiotics in the literature.
Collapse
Affiliation(s)
- Leonard P Rybak
- Department of Otolaryngology, Southern Illinois University School of Medicine, Springfield, IL, United States
| | - Vickram Ramkumar
- Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL, United States
| | - Debashree Mukherjea
- Department of Otolaryngology, Southern Illinois University School of Medicine, Springfield, IL, United States
| |
Collapse
|